ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1590

Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus

David Eldeiry1, Moe Zandy 2, Oshrat Tayer-Shifman 2, Andrew Kwan 3, Sherief Marzouk 2, Jiandong Su 2, Kathleen Bingham 2 and Zahi Touma 2, 1Royal College of Surgeons in Ireland, Dublin, Ireland, 2University Health Network, University of Toronto, Toronto, ON, Canada, 3Queens University, Kingston, ON, Canada

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: depression and anxiety, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In our recent systematic review, we have shown a high prevalence for depression (35%) and anxiety (25.8%) in Systemic Lupus Erythematosus (SLE)1. A better understanding of the SLE phenotypic manifestations associated with depression and anxiety may lead to enhanced early diagnosis and treatment strategies.

Objectives: To determine the overall prevalence of anxiety and depression in a cohort of SLE patients, stratified by SLE-implicated organ systems and to study their associations.

Methods: Patients attending the Toronto Lupus Clinic from August 2017 to January 2019 were studied. Depression and Anxiety were diagnosed with Center for Epidemiological Studies-Depression Scale (cut-off26), BECK Depression Inventory-II (cut-off18), and the BECK Anxiety Inventory (cut-off19). Disease activity was measured with the SLE Disease Activity Index 2000 (SLEDAI-2K). The SLE phenotypic manifestations were stratified based on the organ systems of cumulative 10-year SLEDAI-2K – skin, musculoskeletal (MSK), ocular, neuropsychiatric, and internal organ manifestations (renal, pulmonary, immunologic, and haematologic). Separate multivariate logistic regression analyses (for depression [D], anxiety [A], and comorbid anxiety and depression [AD]) were performed to study the factors associated factors, including age at enrollment, sex, ethnicity, disease duration, inception status (enrolled in the clinic within 1 year of SLE diagnosis), fibromyalgia, and SLE phenotypic manifestations, comparing their significance to the group with neither A or D.

Results: 341 patients (89.7% female), with mean age 45.917.8 years were studied. The prevalence of A and D in the cohort was 34% and 27% respectively, while 21% of the total cohort was found to have AD. Among the 3 outcome groups, MSK system involvement has a significantly higher prevalence when compared to the group with neither A or D (p-values< 0.05). Skin system involvement was also significantly more prevalent among A, D, and AD groups, in comparison to the normal group. Patients with A had significantly higher odds of skin system involvement compared to the normal group (OR=1.8; 95% CI: 1.1, 3.0). Patients with D had higher odds of MSK (OR=1.9; 95% CI: 1.1, 3.5) and skin system involvement (OR=1.8; 95% CI: 1.04, 3.2) compared to the group with neither A or D. Additionally, the odds of skin system involvement was significantly higher among patients with AD, compared to the group with neither (OR=2.0, 95% CI: 1.2, 3.9). In all three models, employment and fibromyalgia were also significant. Age at enrolment was significant in the D and AD models, while inception patient status was significant in the D model exclusively.

Conclusion: SLE phenotypic manifestation, specifically those involving patients’ skin or MSK systems, along with fibromyalgia, socio-demographic factors, and inception status were associated with anxiety or depression. Routine patient screening and evaluation, especially among patients with shorter disease duration, for these associated factors may facilitate the diagnosis of these mental health disorders, and allow for more timely diagnosis and intervention strategies.


Disclosure: D. Eldeiry, None; M. Zandy, None; O. Tayer-Shifman, None; A. Kwan, None; S. Marzouk, None; J. Su, None; K. Bingham, None; Z. Touma, Janssen Research & Development, LLC, 2, Janssen Scientific Affairs, LLC, 2.

To cite this abstract in AMA style:

Eldeiry D, Zandy M, Tayer-Shifman O, Kwan A, Marzouk S, Su J, Bingham K, Touma Z. Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/clinical-and-sociodemographic-associates-of-depression-and-anxiety-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-sociodemographic-associates-of-depression-and-anxiety-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology